About IDEAYA Biosciences
IDEAYA Biosciences is a clinical-stage, oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company specializes in synthetic lethality and integrates small-molecule drug discovery with translational biomarker validation to address genetically defined cancers. Its clinical pipeline includes darovasertib (PKC inhibitor for uveal melanoma), IDE397 (MAT2A), IDE161 (PARG), and other candidates targeting solid tumors with specific molecular vulnerabilities.
Company details
Funding
Total raised
$263M
Last stage
Public
Investors
Founders
Yujiro Hata
Incorporated IDEAYA Biosciences in June 2015 as its first employee and Founder/CEO, led the company's IPO on NASDAQ in May 2019 (NASDAQ: IDYA). Previously COO at Flexus Biosciences (acquired by BMS) and Executive-in-Residence at 5AM Ventures.
Jeff Hager
Co-founder of IDEAYA Biosciences, serving as SVP and Head of Biology, contributing to the company's drug discovery and R&D programs.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.